Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
$5.75
$5.71
$5.12
$9.75
$401.62M0.611 shs2 shs
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
$4.60
$4.60
$4.53
$4.76
$1.56B-0.52N/AN/A
Outokumpu stock logo
OUTKY
Outokumpu
$2.00
$1.89
$1.37
$2.06
$1.83B0.55201 shsN/A
Pharma Mar stock logo
PHMMF
Pharma Mar
$92.57
$93.07
$34.26
$105.60
N/A0.22,471 shs2,500 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
0.00%0.00%0.00%-5.12%-35.47%
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
0.00%0.00%0.00%-3.36%+5.41%
Outokumpu stock logo
OUTKY
Outokumpu
0.00%0.00%+12.99%+5.26%+11.11%
Pharma Mar stock logo
PHMMF
Pharma Mar
0.00%0.00%-10.65%+4.97%+170.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
N/AN/AN/AN/AN/AN/AN/AN/A
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
N/AN/AN/AN/AN/AN/AN/AN/A
Outokumpu stock logo
OUTKY
Outokumpu
N/AN/AN/AN/AN/AN/AN/AN/A
Pharma Mar stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
2.50
Moderate BuyN/AN/A
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
0.00
N/AN/AN/A
Outokumpu stock logo
OUTKY
Outokumpu
1.00
SellN/AN/A
Pharma Mar stock logo
PHMMF
Pharma Mar
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
$1.83B0.22$0.37 per share15.46$5.52 per share1.04
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
$2.69B0.58$0.76 per share6.03$3.79 per share1.21
Outokumpu stock logo
OUTKY
Outokumpu
$6.43B0.28$0.20 per share9.76$4.44 per share0.45
Pharma Mar stock logo
PHMMF
Pharma Mar
$189.23MN/A$0.41 per share223.50$11.62 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
-$172.57MN/A0.00N/AN/AN/AN/AN/A7/15/2025 (Estimated)
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
$74.97MN/A0.00N/AN/AN/AN/A8/5/2025 (Estimated)
Outokumpu stock logo
OUTKY
Outokumpu
-$43.28M-$0.04N/A9.52N/A-0.57%-0.92%-0.56%7/31/2025 (Estimated)
Pharma Mar stock logo
PHMMF
Pharma Mar
$28.27MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)

Latest BHOOY, OERLF, PHMMF, and OUTKY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Outokumpu stock logo
OUTKY
Outokumpu
-$0.01-$0.02-$0.01-$0.02$1.53 billion$1.60 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
N/AN/AN/AN/AN/A
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
N/AN/AN/AN/AN/A
Outokumpu stock logo
OUTKY
Outokumpu
$0.042.00%N/AN/A N/A
Pharma Mar stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
N/AN/AN/A
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
0.15
1.09
0.76
Outokumpu stock logo
OUTKY
Outokumpu
0.12
1.66
0.63
Pharma Mar stock logo
PHMMF
Pharma Mar
0.20
2.97
2.33

Institutional Ownership

CompanyInstitutional Ownership
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
N/A
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
N/A
Outokumpu stock logo
OUTKY
Outokumpu
N/A
Pharma Mar stock logo
PHMMF
Pharma Mar
N/A

Insider Ownership

CompanyInsider Ownership
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
N/A
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
N/A
Outokumpu stock logo
OUTKY
Outokumpu
N/A
Pharma Mar stock logo
PHMMF
Pharma Mar
1.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Boohoo Group Plc Unsponsored ADR stock logo
BHOOY
Boohoo Group
5,07969.85 millionN/ANot Optionable
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
12,064339.76 millionN/ANot Optionable
Outokumpu stock logo
OUTKY
Outokumpu
8,736913.75 millionN/ANot Optionable
Pharma Mar stock logo
PHMMF
Pharma Mar
509N/AN/ANot Optionable

Recent News About These Companies

Pharma Mar’s Strategic Shareholder Meeting
ASCO 25: Jazz, PharmaMar reveal SCLC survival data
Exploring High Growth Tech Stocks In Europe May 2025
Exploring High Growth Tech Stocks in Europe April 2025
Pharma Mar Releases 2024 Director Remuneration Report
High Growth Tech Leads These 3 Top Stocks with Potential
3 Stocks Estimated To Be Up To 48% Below Intrinsic Value
Insider-Led Growth Stocks To Watch In December 2024
Pharma Mar S.A. Reduces Share Capital by Canceling Shares
Pharma Mar Achieves Legal Win in Aplidin Case
PharmaMar gets $10 million milestone from Janssen for Yondelis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Boohoo Group stock logo

Boohoo Group OTCMKTS:BHOOY

$5.75 0.00 (0.00%)
As of 07/7/2025

boohoo group plc, through its subsidiaries, operates as an online clothing retailer in the United Kingdom, rest of Europe, the United States, and internationally. The company designs, sources, markets, and sells clothing, shoes, accessories, and beauty products for 16-to-45-year age customers. It provides its products under the boohoo, boohooMAN, PrettyLittleThing, Nasty Gal, MissPap, Karen Millen, Coast, Oasis, Warehouse, Dorothy Perkins, Wallis, Burton, and Debenhams brands. The company was founded in 2006 and is headquartered in Manchester, the United Kingdom.

Oc Oerlikon Cp stock logo

Oc Oerlikon Cp OTCMKTS:OERLF

$4.60 0.00 (0.00%)
As of 07/3/2025

OC Oerlikon Corporation AG provides surface engineering, polymer processing, and additive manufacturing services in Switzerland, Americas, the Asia-Pacific, and Europe. The company operates through two segments, Surface Solutions and Polymer Processing. It offers engine fan compressors, engine hot section, landing gears, actuation systems, aircraft interior, and hydraulic systems for aerospace; engine and brake systems, transmission, drive train, steering and suspension, exhaust systems, piping and tubing systems, exterior, lighting, green hydrogen, interior, heat exchanger and EGR coolers, peripherals and design parts, and thermal insulation systems for automotive; and oil and gas, and boilers, as well as hydro, gas, steam, and wind turbines for energy industry. In addition, the company offers cutting, metal forming, plastic processing, and die casting for tooling industry; additives, coatings, conductive filler materials, control units, thermal spray systems and components, face to face systems, valve fate systems, hot valves, hot runner systems, single nozzles, stack molds, surface solutions, and valve gates group single nozzles; AM metal powder for additive manufacturing; polymer processing for textile and apparel, functional wear, transportation, packaging, flooring and textile, medical and fiber, and infrastructure; and spine implants, medical, artificial joints, dental and veterinary implants, and surgical and minimally invasive surgical instruments for medical industry. It serves surface solutions under Oerlikon Balzers, Oerlikon Metco, and Oerlikon AM ; and polymer processing solutions under Oerlikon Barmag, Oerlikon Neumag, Oerlikon Nonwoven, and Oerlikon HRSFlow name. OC Oerlikon Corporation AG was founded in 1907 and is headquartered in Pfäffikon, Switzerland.

Outokumpu stock logo

Outokumpu OTCMKTS:OUTKY

$2.00 0.00 (0.00%)
As of 07/3/2025

Outokumpu Oyj produces and sells various stainless steel products in Finland, other European countries, North America, the Asia-Pacific, and internationally. The company operates through three segments: Europe, Americas, and Ferrochrome. It offers cold rolled coils, strips, and sheets; hot rolled coils, strips, and plates; quarto plates; precision strips; and specialized components, such as welded stainless-steel I-beams, H-beams, hollow-section tubes, bent profiles, structural sections, hardened and customized press plates, suction roll shells, and blancs and disks. The company also provides stainless steel powder which includes Supra 316L, Dura 17-4PH, Ultra 904L, Therma 253MA, Dura 4116, and Ni-free austenitic stainless steel powder; and nickel-based alloys. Its products are used in various applications, including commercial kitchen, cooking, food industry, and home appliances; automotive and transportation; building and infrastructure; energy; marine; and heavy industries. The company was founded in 1910 and is headquartered in Helsinki, Finland.

Pharma Mar stock logo

Pharma Mar OTCMKTS:PHMMF

$92.57 0.00 (0.00%)
As of 07/7/2025

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.